Brokerages expect Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) to post earnings per share of ($1.09) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Deciphera Pharmaceuticals’ earnings. The highest EPS estimate is ($1.03) and the lowest is ($1.19). Deciphera Pharmaceuticals posted earnings per share of ($0.65) during the same quarter last year, which indicates a negative year-over-year growth rate of 67.7%. The company is scheduled to report its next earnings report on Tuesday, August 6th.
On average, analysts expect that Deciphera Pharmaceuticals will report full-year earnings of ($4.57) per share for the current financial year, with EPS estimates ranging from ($5.13) to ($4.27). For the next fiscal year, analysts anticipate that the business will report earnings of ($4.14) per share, with EPS estimates ranging from ($5.08) to ($2.46). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for Deciphera Pharmaceuticals.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by ($0.41).
In other news, CFO Thomas Patrick Kelly sold 2,100 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $25.20, for a total value of $52,920.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Over the last three months, insiders sold 17,250 shares of company stock worth $403,813. Insiders own 7.02% of the company’s stock.
Large investors have recently bought and sold shares of the company. Orbimed Advisors LLC increased its position in Deciphera Pharmaceuticals by 25.0% during the fourth quarter. Orbimed Advisors LLC now owns 2,442,200 shares of the company’s stock worth $51,262,000 after purchasing an additional 488,700 shares during the last quarter. Millennium Management LLC increased its position in Deciphera Pharmaceuticals by 1,405.1% during the fourth quarter. Millennium Management LLC now owns 1,246,640 shares of the company’s stock worth $26,167,000 after purchasing an additional 1,163,815 shares during the last quarter. BlackRock Inc. increased its position in Deciphera Pharmaceuticals by 73.6% during the fourth quarter. BlackRock Inc. now owns 1,173,245 shares of the company’s stock worth $24,625,000 after purchasing an additional 497,427 shares during the last quarter. Norges Bank acquired a new stake in Deciphera Pharmaceuticals during the fourth quarter worth about $6,974,000. Finally, Sofinnova Investments Inc. acquired a new stake in Deciphera Pharmaceuticals during the fourth quarter worth about $5,572,000. 58.89% of the stock is currently owned by hedge funds and other institutional investors.
DCPH opened at $22.49 on Thursday. The company has a current ratio of 9.55, a quick ratio of 9.55 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $875.29 million, a P/E ratio of -7.98 and a beta of 2.36. Deciphera Pharmaceuticals has a 52-week low of $18.55 and a 52-week high of $41.27. The firm’s fifty day moving average is $23.23.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.
Read More: Trading Ex-Dividend
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.